期刊
HEART RHYTHM
卷 13, 期 5, 页码 1166-1171出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hrthm.2016.01.018
关键词
Renal denervation; Cardiac arrhythmia; Hypertension; Neural recording; Sympathetic nerve activity
资金
- HSRLCE/HSBC undergraduate research award
- Heart and Stroke Foundation of Canada
Renal denervation (RDN) was primarily developed to treat hypertension and is potentially a new method for treating arrhythmias. Because of the lack of a standardized protocol to measure renal sympathetic nerve activity, RDN is administered in a blind manner. This inability to assess efficacy at the time of treatment delivery may be a large contributor to the ambiguity of RDN outcomes reported in the hypertension literature. The advancement of RDN as a treatment of hypertension or arrhythmias will be hampered by the lack of delivery assessment, a deficiency that the cardiovascular electrophysiology community, with its expertise in recording and mapping, may have a role in addressing and overcoming. The development of endovascular recording of renal nerve action potentials may provide a useful accessory tool for RDN. Innovation in this area will be crucial as we as a community reconsider the therapeutic value of RDN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据